Health
Researchers in Japan compare two seroprevalence antibody tests for SARS-CoV-2 – News-Medical.Net
Researchers have shown that using reliable antibody tests in conjunction is an effective way to estimate seroprevalence in low prevalence settings.
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in Wuhan, China, in December 2019. It has since spread to 192 countries and territories, infecting over 100 million individuals and claiming over 2.2 million lives. To date, Japan has reported 391,945 cases and 5,833 deaths.
A team of researchers in Japan have developed commercially available antibody tests to estimate the seroprevalence of SARS-CoV-2 infection…
-
Business21 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News20 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General15 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News17 hours agoTips to improve engagement – Proctor